Stay updated on BGB324 with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the BGB324 with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the BGB324 with Pembrolizumab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check11 days agoChange DetectedA notice announces that NIH is transitioning from “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.SummaryDifference1%

- Check18 days agoChange DetectedThe ClinicalTrials.gov footer revision updates from v3.7.1 to v3.7.2 while the study record continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check46 days agoChange DetectedThe NCT02872259 study page now displays a 403 Forbidden error instead of the study record content, with the standard header/footer shown; the content previously containing the trial details has been removed.SummaryDifference19%

- Check53 days agoChange DetectedThe page adds links and references to Melanoma-related topics and MedlinePlus Genetics resources, providing readers with external health information related to the study topic.SummaryDifference0.2%

Stay in the know with updates to BGB324 with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BGB324 with Pembrolizumab in Melanoma Clinical Trial page.